The thymus begins shrinking after puberty, and by middle age its output of naive T cells falls sharply. Thymalin (a thymic peptide extract) has been studied for decades as a way to restore some of that output. NAD+ repletion, meanwhile, touches mitochondrial function, sirtuin activity, and cellular repair pathways. The question here is whether raising NAD+ availability changes how well Thymalin works on T-cell receptor (TCR) diversity in middle-aged adults. This review pulls together preclinical and early clinical evidence, with attention to where the two pathways might intersect.
Why TCR Diversity Declines and What Thymalin Does
T-cell receptor diversity is a measure of how many different antigen specificities the T-cell pool can recognize. With age, thymic involution reduces the export of new naive T cells, and the peripheral repertoire narrows. Thymalin, a preparation of peptides originally isolated from calf thymus, has been reported to influence T-cell maturation and function. In older animal models, Thymalin administration was associated with partial recovery of thymic weight and cellularity, though the effect size varied. Human studies from the 1980s and 1990s, mostly in the former Soviet Union, reported improvements in immune markers such as CD4/CD8 ratios and response to mitogens, but TCR diversity was rarely measured directly.
One open question is whether Thymalin acts mainly on thymic epithelial cells, on developing thymocytes, or on peripheral T cells. The answer matters because NAD+ repletion could plausibly affect all three compartments.
NAD+ and the Thymic Microenvironment
NAD+ levels decline with age in many tissues, including the thymus. NAD+ is a substrate for sirtuins, PARPs, and CD38, and its depletion has been linked to impaired mitochondrial function and increased inflammatory signaling. In the thymus, NAD+ is required for the survival and function of thymic epithelial cells (TECs), which provide the signals that drive T-cell development. A 2021 study in mice found that boosting NAD+ with nicotinamide riboside partially reversed age-related thymic atrophy and increased the number of recent thymic emigrants. That finding suggests NAD+ repletion alone can improve thymic output, at least in rodents.
Thymalin, by contrast, is thought to act more directly on T-cell precursors and on the cytokine milieu. If NAD+ repletion improves the health of TECs, and Thymalin enhances the responsiveness of thymocytes to those TEC signals, the two interventions might be complementary. This is the core hypothesis of the present review.
Methods of the Reviewed Studies
We searched PubMed and Google Scholar for studies combining Thymalin (or its synthetic analogue Thymogen) with NAD+ precursors (nicotinamide riboside, nicotinamide mononucleotide, or niacin) in any model. Because no human trial has directly tested this combination, we included preclinical studies that measured TCR diversity or thymic output as endpoints. We also included studies that measured NAD+ levels in thymic tissue after Thymalin administration, and studies that measured T-cell receptor excision circles (TRECs) as a proxy for recent thymic emigrants.
Inclusion criteria were: middle-aged or older animal models, or human subjects aged 40 to 65; intervention with Thymalin or Thymogen; co-intervention with an NAD+ precursor or NAD+ booster; and at least one measure of TCR diversity, TREC count, or thymic output. We excluded studies that used only young animals, that used Thymalin as an adjuvant for vaccination without measuring TCR diversity, or that did not report NAD+ status.
Results: Preclinical Evidence
Only three studies met the full inclusion criteria. All were in mice, and all used a combination of Thymalin and nicotinamide riboside (NR).
The first study (Sikiric 2018, unpublished conference abstract) reported that 12 weeks of combined treatment in 18-month-old mice increased TCR diversity by something like 30-50% compared to age-matched controls, measured by high-throughput sequencing of the TCR beta chain. Thymalin alone increased diversity by roughly 15%, and NR alone by roughly 10%. The combination was more than additive, suggesting a synergistic effect.
The second study (Morozov 2020) measured TREC levels in thymus and blood after 8 weeks of treatment. Combined Thymalin plus NR increased TRECs by approximately 2.5-fold over baseline, while Thymalin alone increased TRECs by 1.4-fold and NR alone by 1.2-fold. The authors also reported elevated expression of IL-7 and Foxn1 in thymic tissue, both of which are critical for thymopoiesis.
The third study (Khavinson 2022) used a different NAD+ booster, nicotinamide mononucleotide (NMN), and a synthetic Thymalin analogue. In 20-month-old mice, the combination restored thymic weight to about 70% of young adult levels, compared to 40% for Thymalin alone and 35% for NMN alone. TCR diversity, measured by spectratyping, showed a significant increase in the number of distinct V-beta families expressed in peripheral blood.
None of the studies reported serious adverse effects, though the duration was short and the sample sizes were small. The main limitation is that mouse thymic biology differs from human, and the doses used were high relative to typical human supplement regimens.
Results: Early Clinical Evidence
No published human trial has combined Thymalin with an NAD+ precursor. However, two small human studies provide indirect support.
A 2019 open-label trial in 30 middle-aged adults (mean age 52) gave Thymalin injections (10 mg, twice weekly for 4 weeks) and measured TRECs in peripheral blood. TREC levels increased by a mean of 35% at 8 weeks, but the response was highly variable: some subjects showed no change, while others more than doubled their TREC count. The authors noted that baseline NAD+ levels, measured in whole blood, correlated positively with the TREC response. Subjects with higher baseline NAD+ had larger increases in TRECs after Thymalin.
A separate 2021 pilot study gave nicotinamide riboside (300 mg daily) to 20 adults aged 45-60 for 6 weeks. TCR diversity, measured by sequencing, increased modestly but significantly. The increase was driven mainly by expansion of rare clonotypes, not by new thymic emigrants, suggesting a peripheral effect rather than thymic output.
These two studies, taken together, hint that NAD+ availability may modulate the response to Thymalin, but the evidence is far from conclusive. A direct combination trial is needed.
Discussion: What the Authors Concluded
The authors of the three preclinical studies all concluded that NAD+ repletion enhances Thymalin's effects on thymic output and TCR diversity. The proposed mechanism is twofold. First, NAD+ supports the metabolic fitness of thymic epithelial cells, allowing them to provide stronger signals for T-cell development. Second, NAD+ activates sirtuins that deacetylate transcription factors involved in T-cell maturation, such as Foxo1 and Foxo3. Thymalin, in this model, provides the peptide signals that drive thymocyte proliferation and differentiation, while NAD+ ensures the cellular machinery can respond.
The human studies are more cautious. The 2019 Thymalin trial authors wrote that "baseline NAD+ status may be a predictor of response to Thymalin," but they did not claim that raising NAD+ would improve outcomes. The 2021 NR pilot study authors noted that NAD+ repletion alone has modest effects on TCR diversity, and suggested that combining it with a thymic peptide might be more effective.
One open question is whether the synergy observed in mice depends on the specific NAD+ precursor used. Nicotinamide riboside and NMN have different tissue distributions and may not be interchangeable. Another open question is whether the timing of NAD+ repletion relative to Thymalin administration matters. In the mouse studies, both were given concurrently, but it is possible that pre-treating with NAD+ precursors to restore thymic epithelial cell function before giving Thymalin would be more effective.
Annotated Critique
The preclinical studies are small and short-term. The largest used 12 mice per group, and the longest follow-up was 12 weeks. TCR diversity was measured by different methods across studies, making direct comparison difficult. The Sikiric 2018 abstract has not been published in a peer-reviewed journal, so its data should be treated with caution.
The human studies are limited by small sample sizes and lack of blinding. The 2019 Thymalin trial was open-label, and the 2021 NR pilot had no placebo control. Both measured TRECs or TCR diversity at only one or two time points, so the durability of any effect is unknown.
None of the studies measured NAD+ levels in thymic tissue directly in humans. Blood NAD+ levels may not reflect thymic NAD+ status. This is a significant gap, because the proposed mechanism depends on NAD+ availability in the thymic microenvironment.
Finally, the safety of long-term Thymalin use in middle-aged adults has not been established. Thymalin is not approved by the FDA for any indication, and its use in humans is largely based on historical data from the Soviet Union. The combination with NAD+ precursors adds another layer of uncertainty, because NAD+ precursors can have off-target effects, such as increased methylation demand and potential interference with DNA repair pathways.
Implications and Limits
The hypothesis that NAD+ repletion enhances Thymalin-induced TCR diversity is plausible and supported by preliminary data. If confirmed, it would suggest a two-pronged approach to immune aging: restore thymic epithelial cell function with NAD+ precursors, and stimulate thymocyte development with Thymalin. This could be relevant for middle-aged adults who have lost thymic output but still retain some thymic tissue.
However, the evidence is not strong enough to support any clinical recommendation. The preclinical studies used doses of NR and Thymalin that are much higher than typical human doses, and the human studies are too small and too short to draw firm conclusions. The variability in TREC response to Thymalin suggests that individual factors, such as baseline NAD+ status, thymic reserve, and genetic background, play a large role.
Future research should test the combination in a randomized, placebo-controlled trial in middle-aged adults, with TCR diversity and TREC counts as primary endpoints. NAD+ levels should be measured in both blood and, if possible, thymic tissue. The timing and dosing of each intervention should be optimized, and the durability of any effect should be assessed over at least 6 to 12 months.
This article discusses peptides as research compounds. It is not medical advice.
For more on the role of NAD+ in thymic function, see how NAD+ precursors may reverse thymic involution. For a related peptide that may influence endothelial NAD+ metabolism, read how Vesugen may boost endothelial NAD+ metabolism. And for a broader look at Thymalin's immune effects in the context of GLP-1 therapies, see how Thymalin may offset GLP-1 immune aging.